Report of Foreign Issuer (6-k)
March 24 2017 - 9:30AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
March 24, 2017
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo Nordisk receives positive opinion from the European
regulatory authorities for Refixia® (nonacog beta pegol, N9-GP) for the treatment of haemophilia B
Bagsværd, Denmark, 24 March 2017
– Novo Nordisk today
announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), adopted a
positive opinion for the use of Refixia
®
(nonacog beta pegol, N9-GP), recommending marketing
authorisation for the treatment of adolescents and adults with haemophilia B.
The CHMP recommends Refixia
®
,
the brand name for nonacog beta pegol, N9-GP, to be indicated for prophylaxis and on-demand treatment of bleeding as well as for
surgical procedures in adolescent (≥12 years of age) and adult patients with haemophilia B (congenital factor IX deficiency).
The recommendation is based on the results from the paradigm clinical trial programme, where 115 previously treated children and
adults with haemophilia B were treated with Refixia
®
.
“We are excited about the positive opinion obtained for Refixia
®
and it represents a significant milestone in our efforts to expand the treatment options for patients with haemophilia,”
said Mads Krogsgaard Thomsen, executive vice president and chief scientific officer of Novo Nordisk. “We believe Refixia
®
with its strong clinical profile provides haemophilia B patients better protection against bleeds, even into damaged joints,
and an overall improved quality of life.”
About Refixia
®
Refixia
®
(nonacog
beta pegol, N9-GP) is an extended half-life factor IX molecule for replacement therapy in patients with haemophilia B.
Glycopegylation, the prolongation technology used for the half-life extension, is a novel approach in haemophilia B.
Pegylated products have been approved in haemophilia A and other therapeutic areas. The review of Refixia
®
was
based on the paradigm programme, a phase 3 clinical programme enrolling children and adults with severe or moderately severe
haemophilia B. In the programme, 115 previously treated patients had a total of more than 8,800 exposure days for up to 2.7
years of treatment with Refixia
®
.
Page 2 of 2
About Novo Nordisk
Novo Nordisk is a global healthcare
company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities
that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered
in Denmark, Novo Nordisk employs approximately 42,000 people in 77 countries and markets its products in more than 165 countries.
For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
Further information
Media:
|
|
|
Katrine Sperling
|
+45 3079 6718
|
krsp@novonordisk.com
|
Ken Inchausti (US)
|
+1 609 786 8316
|
kiau@novonordisk.com
|
|
|
|
Investors
:
|
|
|
Peter Hugreffe Ankersen
|
+45 3075 9085
|
phak@novonordisk.com
|
Hanna Ögren
|
+45 3079 8519
|
haoe@novonordisk.com
|
Anders Mikkelsen
|
+45 3079 4461
|
armk@novonordisk.com
|
Kasper Veje (US)
|
+1 609 235 8567
|
kpvj@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 22 / 2017
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: March 24, 2017
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2023 to Apr 2024